Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yan-Ruide Li

Showing results (71-80 of 92) with videos related to

Pageof 10
Sort By:
Research (Washington, D.C.)|June 15, 2026
Rejuvenated Hematopoietic Stem and Progenitor Cell-Engineered CAR-Armored Natural Killer T Cells for Malignant Pleural MesotheliomaYan-Ruide Li, Yichen Zhu, Zhe Li, et al.
Signal Transduction and Targeted Therapy|March 14, 2026
Spatiotemporal profiling reveals distinct dynamics and checkpoint regulations of CAR-T and CAR-NKT cells against solid tumorsYan-Ruide Li, Miao Li, Yuning Chen, et al.
Circulation Research|April 30, 2025
Habitual Exercise Modulates Neuroimmune Interaction to Mitigate Aortic StiffnessJae Min Cho, Khoa Vu, Seul-Ki Park, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 14, 2025
Allogeneic stem cell-engineered EGFRvIII-specific CAR-NKT cells for treating glioblastoma with enhanced efficacy and safetyYan-Ruide Li, Yichen Zhu, Zhe Li, et al.
Nature Communications|June 11, 2021
Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapyYu-Chen Wang, Xi Wang, Jiaji Yu, et al.
Iscience|April 20, 2026
Creatine uptake promotes dendritic cell activation and enhances antitumor immunityElliot Kang, James Elsten-Brown, Yu-Chen Wang, et al.
Iscience|October 9, 2023
Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy designYan-Ruide Li, Christopher J Ochoa, Yichen Zhu, et al.
Nature Nanotechnology|September 23, 2024
Biomimetic cell stimulation with a graphene oxide antigen-presenting platform for developing T cell-based therapiesEnbo Zhu, Jiaji Yu, Yan-Ruide Li, et al.
Nature Communications|November 8, 2023
Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineeringDerek Lee, Zachary Spencer Dunn, Wenbin Guo, et al.
Nature Communications|February 1, 2025
Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignanciesYan-Ruide Li, Ying Fang, Siyue Niu, et al.
Pageof 10

Showing results (71-80 of 92) with videos related to

Sort By:
Pageof 10
Research (Washington, D.C.)|June 15, 2026
Rejuvenated Hematopoietic Stem and Progenitor Cell-Engineered CAR-Armored Natural Killer T Cells for Malignant Pleural MesotheliomaYan-Ruide Li, Yichen Zhu, Zhe Li, et al.
Signal Transduction and Targeted Therapy|March 14, 2026
Spatiotemporal profiling reveals distinct dynamics and checkpoint regulations of CAR-T and CAR-NKT cells against solid tumorsYan-Ruide Li, Miao Li, Yuning Chen, et al.
Circulation Research|April 30, 2025
Habitual Exercise Modulates Neuroimmune Interaction to Mitigate Aortic StiffnessJae Min Cho, Khoa Vu, Seul-Ki Park, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 14, 2025
Allogeneic stem cell-engineered EGFRvIII-specific CAR-NKT cells for treating glioblastoma with enhanced efficacy and safetyYan-Ruide Li, Yichen Zhu, Zhe Li, et al.
Nature Communications|June 11, 2021
Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapyYu-Chen Wang, Xi Wang, Jiaji Yu, et al.
Iscience|April 20, 2026
Creatine uptake promotes dendritic cell activation and enhances antitumor immunityElliot Kang, James Elsten-Brown, Yu-Chen Wang, et al.
Iscience|October 9, 2023
Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy designYan-Ruide Li, Christopher J Ochoa, Yichen Zhu, et al.
Nature Nanotechnology|September 23, 2024
Biomimetic cell stimulation with a graphene oxide antigen-presenting platform for developing T cell-based therapiesEnbo Zhu, Jiaji Yu, Yan-Ruide Li, et al.
Nature Communications|November 8, 2023
Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineeringDerek Lee, Zachary Spencer Dunn, Wenbin Guo, et al.
Nature Communications|February 1, 2025
Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignanciesYan-Ruide Li, Ying Fang, Siyue Niu, et al.
Pageof 10